AstraZeneca’s Bristol Myers pursuit sets the week’s M&A stakes

The week’s central M&A question was whether scale can overcome execution and regulatory risk, with AstraZeneca-Bristol Myers and Paramount-Warner Bros. Discovery both becoming high-stakes tests. AstraZeneca’s proposal stayed exploratory, while Paramount-Warner Bros. Discovery cleared the United Kingdom but remained delayed by US legal proceedings.

Private equity and take-private activity supplied the clearest completed transactions, as Electronic Arts and easyJet changed ownership after financing or bidding battles. The week also paired capability expansion with execution demands, from Visa’s fraud push and Dream Finders’ promised savings to OpenAI’s recurring NextSlide acquisition.